Given that VEGFR-targeted therapy remains the first-line therapeutic choice for advanced ccRCC, we compared the sensitivity of sorafenib, sunitinib, pazopanib, and axitinib across high- and low-risk groups. This evidence concerns the gene KDR and nonpapillary renal cell carcinoma.